← Back to headlines
UBS Upgrades Argenx Stock on Strong Vyvgart Sales Forecast
Investment bank UBS has upgraded its rating on pharmaceutical company Argenx, citing robust market potential for its drug Vyvgart. Analysts predict the medication could reach $20 billion in peak annual sales, driving optimism around the company's financial outlook.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
